| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellness Survey at the Psych Congress 2025.
The analysis found that nearly half (48%) of respondents with severe GAD symptoms reported experiencing SI almost every day. The study also revealed that 65% of those reporting GAD symptoms also reported major depressive disorder (MDD) symptoms. Among those with GAD, 78% with moderate symptoms and 91% of those with severe symptoms reported SI within the past two weeks. Rates remained high among those reporting both GAD and MDD symptoms, in whom 75% with moderate and 85% with severe GAD reported SI.
Suicide is one of the leading causes of death among U.S. adults, especially those aged 44 years or younger.1 SI involves thinking about or planning to commit suicide. SI is a growing public health issue, particularly among individuals with mental health conditions.2,3
"While SI has been extensively studied in people with MDD, far less is known about its impact on those with GAD with or without comorbid MDD," said Erin Ferries, Ph.D., lead author and Head of Healthcare Economics Outcomes Research (HEOR) at MindMed. "These findings highlight the urgent need to address the gaps in routine suicide risk screening, particularly among people living with GAD and MDD, as SI appears to be more prevalent in these individuals than previously understood. During Suicide Prevention Month, we are reminded that stronger identification and timely, targeted interventions are essential to reaching those most at risk—and may help save lives."
The analysis also showed that nearly one in three U.S. adults (28.4%) reported experiencing SI. Rates were highest among men (33%), young adults aged 18 to 34 years (47.5%), Hispanic individuals (47.6%), and students (42.9%). Additionally, nearly a quarter (23%) of the total sample reported moderate or severe GAD symptoms.
About the Study
The NHWS is an annual, nationally representative, online-based survey in which all data are self-reported. Recruitment is designed to represent the general US adult (age >18) population in terms of age, race/ethnicity, and gender distributions. Data were reported by NHWS respondents on 1) demographics, 2) GAD and MDD experience and diagnosis, 3) GAD treatment use, 4) 7-item GAD Questionnaire (GAD-7), and 5) 9-item Patient Health Questionnaire (PHQ-9).
The results were weighted to project to the U.S. general adult population. Overall, 75,261 U.S. adults who completed the 2022 NHWS were included in the study analyses, which projected to approximately 253.15 million adults. The GAD-only cohort included 10,450 adults, which projected to 31.87 million, with the GAD and MDD cohort including 18,060 adults, which projected to 60.04 million.
Posted In: MNMD
